表紙
市場調查報告書

類血友病(vWD)治療的全球市場:去氨加壓素,血栓穩定化劑,補充療法,避孕藥 - 產業分析,市場規模,佔有率,成長,趨勢,預測,2019年∼2027年

von Willebrand Disease Treatment Market (Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 897463
出版日期 內容資訊 英文 241 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類血友病(vWD)治療的全球市場:去氨加壓素,血栓穩定化劑,補充療法,避孕藥 - 產業分析,市場規模,佔有率,成長,趨勢,預測,2019年∼2027年 von Willebrand Disease Treatment Market (Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年07月10日內容資訊: 英文 241 Pages
簡介

本報告提供全球全球類血友病(vWD)治療市場調查,提供市場概要,各疾病類型·醫藥品·給藥途徑·性別·流通管道·各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義和範圍
  • 市場區隔
  • 主要的調查目的
  • 調查的重點

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 病定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 市場分析及預測
    • 市場收益預測

第5章 主要洞察

  • 臨床試驗分析
  • 在主要國家的全球性疾病罹患率
  • 全球類血友病(vWD)治療藥的開發平台分析
  • 主要產業活動
  • 年度平均治療費
  • 償付方案:全體·各地區
  • 疾病概要
  • 今後預測
  • 法規方案:全體·各地區
  • 對月經過多患者的治療選項

第6章 全球類血友病(vWD)治療市場:各疾病類型

  • 簡介和定義
  • 主要調查結果/開發
  • 市場規模的變化與預測:各疾病類型
    • 第一型 vWD
    • 第二型 vWD
    • 第三型 vWD
    • 後天性 vWD
  • 市場魅力分析:各疾病類型

第7章 全球類血友病(vWD)治療市場:各類醫藥品

  • 簡介和定義
  • 主要調查結果/開發
  • 市場規模的變化與預測:各類醫藥品
    • 去氨加壓素
    • 血栓穩定化劑
    • 補充療法
    • 避孕藥
    • 其他
  • 市場魅力分析:各類醫藥品

第8章 全球類血友病(vWD)治療市場:各給藥途徑

  • 簡介和定義
  • 主要調查結果/開發
  • 市場規模的變化與預測:各給藥途徑
    • 口服
    • 注射
    • 其他
  • 市場魅力分析:各給藥途徑

第9章 全球類血友病(vWD)治療市場:性別

  • 簡介和定義
  • 主要調查結果/開發
  • 市場規模的變化與預測:性別
    • 男性
    • 女性
  • 市場魅力分析:性別

第10章 全球類血友病(vWD)治療市場:各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 市場規模的變化與預測:各流通管道
    • 線上藥局
    • 零售藥局
    • 醫院藥局
  • 市場魅力分析:各流通管道

第11章 全球類血友病(vWD)治療市場:各地區

  • 主要調查結果
  • 市場規模的變化與預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第12章 北美

第13章 歐洲

第14章 亞太地區

第15章 南美

第16章 中東·非洲

第17章 競爭情形

  • 市場播放器
  • 市場佔有率分析:各企業
  • 企業簡介
    • Octapharma AG
    • Grifols, SA
    • Shire plc
    • Baxter
    • Novo Nordisk A/S
    • Bayer AG
    • Sanofi, Kedrion SpA
    • CSL Behring
    • Pfizer, Inc.
    • Ferring BV
    • Other Prominent Players
目錄

Title:
von Willebrand Disease Treatment Market (Disease Type: Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease, and Acquired von Willebrand Disease; Drug: Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others; Route of Administration: Oral, Injection, and Other; Gender: Men and Women; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

TMR's recent report on the von Willebrand disease treatment market offers readers an overall market overview with the help of comprehensive analysis of the global market. The TMR study on the von Willebrand disease treatment market evaluates the market with respect to the historical and current market scenario, and provides a forecast for the period of 2019-2027. Report audiences are able to make key business decisions with the help of the findings and exclusive von Willebrand disease treatment market insights included in the report. TMR's report also provides an assessment of the key von Willebrand disease treatment market dynamics that are likely to impact the market in the future. The report also offers a thorough understanding of the key industry trends and developments made by von Willebrand disease treatment market players. The TMR report is divided into vital sections, which allows readers to gain an individual understanding of the von Willebrand disease treatment market.

Key Questions Answered in the Report:

  • What are key trends that are likely to influence the von Willebrand disease treatment market in the coming five years?
  • Which disease type is expected to prevail in the von Willebrand disease treatment market?
  • How much will the von Willebrand disease treatment market value in the year 2027?
  • Which regions are likely to generate major sales opportunities for von Willebrand disease treatment market players?
  • What are the key developments carried out by leading von Willebrand disease treatment market contributors?

The first section in the study on the von Willebrand disease treatment market includes a preface that provides a brief market overview, including definition and scope of the market. This chapter highlights the key research objectives that allow readers to gain a concise market understanding. Following this section is the executive summary that sheds light on the von Willebrand disease treatment market aspects covered in the report. The next chapter in the von Willebrand disease treatment market report is the market overview, which offers a glance into the market in terms of key von Willebrand disease treatment market dynamics such as drivers, opportunistic avenues, and restraining factors.

The next chapter offers an outlook of the global von Willebrand disease treatment market analysis and forecast in terms of volume and value. Following this overview is the market outlook in terms of the regulatory scenario in different regions, along with the global reimbursement scenario. Following this is a detailed segmentation analysis of the von Willebrand disease treatment market. The evaluation includes bifurcation on the basis of disease type, drug, route of administration, gender, distribution channel, and region. The evaluation of key segments in the von Willebrand disease treatment market and inclusion of year-on-year growth projection, along with basis point share analysis, further helps clients identify lucrative avenues.

The TMR study on the von Willebrand disease treatment market offers an assessment of the geographical landscape of the market. The regional assessment helps market players make strategic decisions pertaining to their expansion strategies and investments. Segment-wise and country-level assessment of individual regions helps audiences of the von Willebrand disease treatment market study evaluate the potential of the market. Backed by year-on-year growth projections, and global value and volume share, this section is a significant part of the report on the von Willebrand disease treatment market.

The study on the von Willebrand disease treatment market provides a holistic competitive assessment, providing details of leading market players. This sections highlights the nature of the von Willebrand disease treatment market with the help of the market share held by leading, emerging, and new players. The dashboard view of the competitive landscape in the von Willebrand disease treatment market report allows readers to assess the strategies implemented by players and their performance in the von Willebrand disease treatment market, featuring focus areas of the von Willebrand disease treatment market players. The competitive structure of prominent players in the von Willebrand disease treatment market is also discussed in the study.

Research Methodology

The TMR report on the von Willebrand disease treatment market is based on an in-depth evaluation of the market, including comprehensive primary and secondary research. Detailed evaluation of the von Willebrand disease treatment market in terms of competitive landscape is backed by individual-level analysis of various aspects related to the market. An evaluation of the historical and current market scenario for von Willebrand disease treatment, focusing on key market segments, major regions, and market dynamics, along with other qualitative inputs, helps TMR analysts derive vital predictions and offer a forecast analysis for the von Willebrand disease treatment market. Report audiences can access the von Willebrand disease treatment market study to gain a forecasted market assessment for the period of 2019-2027.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global von Willebrand Disease Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Disease Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global von Willebrand Disease Treatment Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Clinical Trial Analysis of von Willebrand Disease
  • 5.2. Disease Prevalence Rate Globally with key countries
  • 5.3. Pipeline Analysis of von Willebrand Disease
  • 5.4. Key Industrial Events (Licensing & Acquisitions)
  • 5.5. Average Annual Cost of Therapy
  • 5.6. Reimbursement Scenario, by Region/globally
  • 5.7. Disease Overview
  • 5.8. Future Prospects Assessment
  • 5.9. Regulatory Scenario, by Region/globally
  • 5.10. Treatment Options for Women with Menorrhagia in von Willebrand Disease

6. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Disease Type, 2017-2027
    • 6.3.1. Type 1 vWD
    • 6.3.2. Type 2 vWD
    • 6.3.3. Type 3 vWD
    • 6.3.4. Acquired vWD
  • 6.4. Market Attractiveness, by Disease Type

7. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Drug

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug, 2017-2027
    • 7.3.1. Desmopressin
    • 7.3.2. Clot-stabilizing Medications
    • 7.3.3. Replacement Therapies
    • 7.3.4. Contraceptives
    • 7.3.5. Others
  • 7.4. Market Attractiveness, by Drug

8. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2027
    • 8.3.1. Oral
    • 8.3.2. Injection
    • 8.3.3. Other
  • 8.4. Market Attractiveness, by Route of Administration

9. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Gender

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Gender, 2017-2027
    • 9.3.1. Men
    • 9.3.2. Women
  • 9.4. Market Attractiveness, by Gender

10. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2027
    • 10.3.1. Online Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Hospital Pharmacies
  • 10.4. Market Attractiveness, by Distribution Channel

11. Global von Willebrand Disease Treatment Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness, by Country/Region

12. North America von Willebrand Disease Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Disease Type, 2017-2027
    • 12.2.1. Type 1 vWD
    • 12.2.2. Type 2 vWD
    • 12.2.3. Type 3 vWD
    • 12.2.4. Acquired vWD
  • 12.3. Market Value Forecast, by Drug, 2017-2027
    • 12.3.1. Desmopressin
    • 12.3.2. Clot-stabilizing Medications
    • 12.3.3. Replacement Therapies
    • 12.3.4. Contraceptives
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2027
    • 12.4.1. Oral
    • 12.4.2. Injection
    • 12.4.3. Other
  • 12.5. Market Value Forecast, by Gender, 2017-2027
    • 12.5.1. Men
    • 12.5.2. Women
  • 12.6. Market Value Forecast, by Distribution Channel, 2017-2027
    • 12.6.1. Online Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Hospital Pharmacies
  • 12.7. Market Value Forecast, by Country, 2017-2027
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Disease Type
    • 12.8.2. By Drug
    • 12.8.3. By Route of Administration
    • 12.8.4. By Gender
    • 12.8.5. By Distribution Channel
    • 12.8.6. By Country

13. Europe von Willebrand Disease Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Disease Type, 2017-2027
    • 13.2.1. Type 1 vWD
    • 13.2.2. Type 2 vWD
    • 13.2.3. Type 3 vWD
    • 13.2.4. Acquired vWD
  • 13.3. Market Value Forecast, by Drug, 2017-2027
    • 13.3.1. Desmopressin
    • 13.3.2. Clot-stabilizing Medications
    • 13.3.3. Replacement Therapies
    • 13.3.4. Contraceptives
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2027
    • 13.4.1. Oral
    • 13.4.2. Injection
    • 13.4.3. Other
  • 13.5. Market Value Forecast, by Gender, 2017-2027
    • 13.5.1. Men
    • 13.5.2. Women
  • 13.6. Market Value Forecast, by Distribution Channel, 2017-2027
    • 13.6.1. Online Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Hospital Pharmacies
  • 13.7. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Disease Type
    • 13.8.2. By Drug
    • 13.8.3. By Route of Administration
    • 13.8.4. By Gender
    • 13.8.5. By Distribution Channel
    • 13.8.6. By Country/Sub-region

14. Asia Pacific von Willebrand Disease Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Disease Type, 2017-2027
    • 14.2.1. Type 1 vWD
    • 14.2.2. Type 2 vWD
    • 14.2.3. Type 3 vWD
    • 14.2.4. Acquired vWD
  • 14.3. Market Value Forecast, by Drug, 2017-2027
    • 14.3.1. Desmopressin
    • 14.3.2. Clot-stabilizing Medications
    • 14.3.3. Replacement Therapies
    • 14.3.4. Contraceptives
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2027
    • 14.4.1. Oral
    • 14.4.2. Injection
    • 14.4.3. Other
  • 14.5. Market Value Forecast, by Gender, 2017-2027
    • 14.5.1. Men
    • 14.5.2. Women
  • 14.6. Market Value Forecast, by Distribution Channel, 2017-2027
    • 14.6.1. Online Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Hospital Pharmacies
  • 14.7. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 14.7.1. China
    • 14.7.2. India
    • 14.7.3. Japan
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Disease Type
    • 14.8.2. By Drug
    • 14.8.3. By Route of Administration
    • 14.8.4. By Gender
    • 14.8.5. By Distribution Channel
    • 14.8.6. By Country/Sub-region

15. Latin America von Willebrand Disease Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Disease Type, 2017-2027
    • 15.2.1. Type 1 vWD
    • 15.2.2. Type 2 vWD
    • 15.2.3. Type 3 vWD
    • 15.2.4. Acquired vWD
  • 15.3. Market Value Forecast, by Drug, 2017-2027
    • 15.3.1. Desmopressin
    • 15.3.2. Clot-stabilizing Medications
    • 15.3.3. Replacement Therapies
    • 15.3.4. Contraceptives
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2027
    • 15.4.1. Oral
    • 15.4.2. Injection
    • 15.4.3. Other
  • 15.5. Market Value Forecast, by Gender, 2017-2027
    • 15.5.1. Men
    • 15.5.2. Women
  • 15.6. Market Value Forecast, by Distribution Channel, 2017-2027
    • 15.6.1. Online Pharmacies
    • 15.6.2. Retail Pharmacies
    • 15.6.3. Hospital Pharmacies
  • 15.7. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Disease Type
    • 15.8.2. By Drug
    • 15.8.3. By Route of Administration
    • 15.8.4. By Gender
    • 15.8.5. By Distribution Channel
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa von Willebrand Disease Treatment Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Disease Type, 2017-2027
    • 16.2.1. Type 1 vWD
    • 16.2.2. Type 2 vWD
    • 16.2.3. Type 3 vWD
    • 16.2.4. Acquired vWD
  • 16.3. Market Value Forecast, by Drug, 2017-2027
    • 16.3.1. Desmopressin
    • 16.3.2. Clot-stabilizing Medications
    • 16.3.3. Replacement Therapies
    • 16.3.4. Contraceptives
    • 16.3.5. Others
  • 16.4. Market Value Forecast, by Route of Administration, 2017-2027
    • 16.4.1. Oral
    • 16.4.2. Injection
    • 16.4.3. Other
  • 16.5. Market Value Forecast, by Gender, 2017-2027
    • 16.5.1. Men
    • 16.5.2. Women
  • 16.6. Market Value Forecast, by Distribution Channel, 2017-2027
    • 16.6.1. Online Pharmacies
    • 16.6.2. Retail Pharmacies
    • 16.6.3. Hospital Pharmacies
  • 16.7. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Disease Type
    • 16.8.2. By Drug
    • 16.8.3. By Route of Administration
    • 16.8.4. By Gender
    • 16.8.5. By Distribution Channel
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (by Tier and Size of companies)
  • 17.2. Market Share Analysis by Company (2018)
  • 17.3. Company Profiles
    • 17.3.1. Octapharma AG
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. SWOT Analysis
      • 17.3.1.4. Strategic Overview
    • 17.3.2. Grifols, S.A.
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. SWOT Analysis
      • 17.3.2.4. Strategic Overview
    • 17.3.3. Shire plc
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. SWOT Analysis
      • 17.3.3.4. Strategic Overview
    • 17.3.4. Baxter
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. SWOT Analysis
      • 17.3.4.4. Strategic Overview
    • 17.3.5. Novo Nordisk A/S
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. SWOT Analysis
      • 17.3.5.4. Strategic Overview
    • 17.3.6. Bayer AG
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. SWOT Analysis
      • 17.3.6.4. Strategic Overview
    • 17.3.7. Sanofi, Kedrion S.p.A
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. SWOT Analysis
      • 17.3.7.4. Strategic Overview
    • 17.3.8. CSL Behring
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. SWOT Analysis
      • 17.3.8.4. Strategic Overview
    • 17.3.9. Pfizer, Inc.
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. SWOT Analysis
      • 17.3.9.4. Strategic Overview
    • 17.3.10. Ferring B.V.
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. SWOT Analysis
      • 17.3.10.4. Strategic Overview
    • 17.3.11. Other Prominent Players

List of Tables

  • Table 01: Key Mergers & Acquisition in the von Willebrand Disease Treatment Market
  • Table 02: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 03: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 04: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 05: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 06: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 07: Global von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2027
  • Table 08: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2027
  • Table 09: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 10: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 11: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 12: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 13: North America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 14: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 15: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 16: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 17: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 18: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 19: Europe von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 20: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 21: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 22: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 23: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 24: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 25: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 26: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 27: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 28: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 29: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 30: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 31: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 32: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 33: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017-2027
  • Table 34: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 35: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 36: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Gender, 2017-2027
  • Table 37: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2027

List of Figures

  • Figure 01: Global von Willebrand Disease Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 03: Global von Willebrand Disease Treatment Market Value Share, by Disease Type, 2018
  • Figure 04: Global von Willebrand Disease Treatment Market Value Share, by Drug, 2018
  • Figure 05: Global von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018
  • Figure 06: Global von Willebrand Disease Treatment Market Value Share, by Gender, 2018
  • Figure 07: Global von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018
  • Figure 08: Global von Willebrand Disease Treatment Market Value Share, by Region, 2018
  • Figure 09: Regulatory Approval Process - U.S.
  • Figure 10: Regulatory Approval Process - Europe
  • Figure 11: Regulatory Approval Process - Japan
  • Figure 12: Global von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 13: Global von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 14: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Type 1 von Willebrand Disease, 2017-2027
  • Figure 15: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Type 1 von Willebrand Disease, 2017-2027
  • Figure 16: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Type 3 von Willebrand Disease, 2017-2027
  • Figure 17: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Acquired von Willebrand Disease, 2017-2027
  • Figure 18: Global von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 19: Global von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 20: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Desmopressin 2017-2027
  • Figure 21: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Clot-stabilizing Medications, 2017-2027
  • Figure 22: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Replacement Therapies, 2017-2027
  • Figure 23: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Contraceptives, 2017-2027
  • Figure 24: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017-2027
  • Figure 25: Global von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 26: Global von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 27: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Oral, 2017-2027
  • Figure 28: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Injection, 2017-2027
  • Figure 29: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017-2027
  • Figure 30: Global von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2018 and 2027
  • Figure 31: Global von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 32: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Men, 2017-2027
  • Figure 33: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Women, 2017-2027
  • Figure 34: Global von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 35: Global von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 36: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017-2027
  • Figure 37: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017-2027
  • Figure 38: Global von Willebrand Disease Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017-2027
  • Figure 39: Global von Willebrand Disease Treatment Market Value Share, by Region, 2018 and 2027
  • Figure 40: Global von Willebrand Disease Treatment Market Attractiveness, by Region, 2019-2027
  • Figure 41: North America von Willebrand Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 42: North America von Willebrand Disease Treatment Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 43: North America von Willebrand Disease Treatment Market Attractiveness, by Country, 2019-2027
  • Figure 44: North America von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 45: North America von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 46: North America von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 47: North America von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 48: North America von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018 and 2027
  • Figure 49: North America von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 50: North America von Willebrand Disease Treatment Market Value Share, by Gender, 2018 and 2027
  • Figure 51: North America von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 52: North America von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 53: North America von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 54: Europe von Willebrand Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 55: Europe von Willebrand Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 56: Europe von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 57: Europe von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 58: Europe von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 59: Europe von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 60: Europe von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 61: Europe von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018 and 2027
  • Figure 62: Europe von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 63: Europe von Willebrand Disease Treatment Market Value Share, by Gender, 2018 and 2027
  • Figure 64: Europe von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 65: Europe von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 66: Europe von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 67: Asia Pacific von Willebrand Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 68: Asia Pacific von Willebrand Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 69: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 70: Asia Pacific von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 71: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 72: Asia Pacific von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 73: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 74: Asia Pacific von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018 and 2027
  • Figure 75: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 76: Asia Pacific von Willebrand Disease Treatment Market Value Share, by Gender, 2018 and 2027
  • Figure 77: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 78: Asia Pacific von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 79: Asia Pacific von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 80: Latin America von Willebrand Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 81: Latin America von Willebrand Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 82: Latin America von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 83: Latin America von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 84: Latin America von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 85: Latin America von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 86: Latin America von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 87: Latin America von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018 and 2027
  • Figure 88: Latin America von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 89: Latin America von Willebrand Disease Treatment Market Value Share, by Gender, 2018 and 2027
  • Figure 90: Latin America von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 91: Latin America von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 92: Latin America von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 93: Middle East & Africa von Willebrand Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019-2027
  • Figure 94: Middle East & Africa von Willebrand Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 95: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 96: Middle East & Africa von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2018 and 2027
  • Figure 97: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2019-2027
  • Figure 98: Middle East & Africa von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2018 and 2027
  • Figure 99: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Drug, 2019-2027
  • Figure 100: Middle East & Africa von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2018 and 2027
  • Figure 101: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 102: Middle East & Africa von Willebrand Disease Treatment Market Value Share, by Gender, 2018 and 2027
  • Figure 103: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Gender, 2019-2027
  • Figure 104: Middle East & Africa von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 105: Middle East & Africa von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2019-2027
Back to Top